Inhibitor of apoptosis (IAP) proteins are expressed at high levels in many cancers and therefore represent attractive targets for therapeutic intervention. Here, we report for the first time that the second mitochondria-derived activator of caspases (Smac) mimetic BV6 sensitizes glioblastoma cells toward Temozolomide (TMZ), the first-line chemotherapeutic agent in the treatment of glioblastoma. BV6 and TMZ synergistically reduce cell viability and trigger apoptosis in glioblastoma cells (combination index o0.4 --0.8), which is accompanied by increased loss of mitochondrial-membrane potential, cytochrome c release, caspase activation and caspase-dependent apoptosis. Analysis of the molecular mechanisms reveals that BV6 causes rapid degradation of cIAP1, leading to stabilization of NF-kB-inducing kinase and NF-kB activation. BV6-stimulated NF-kB activation is critically required for sensitization toward TMZ, as inhibition of NF-kB by overexpression of the mutant IkBa super-repressor profoundly reduces loss of mitochondrial membrane potential, cytochrome c release, caspase activation and apoptosis. Of note, BV6-mediated sensitization to TMZ is not associated with increased tumor necrosis factor alpha (TNFa) production. Also, TNFa, CD95 or TRAIL-blocking antibodies or knockdown of TNFR1 have no or little effect on combination treatment-induced apoptosis. Interestingly, BV6 and TMZ cooperate to trigger the formation of a RIP1 (receptor activating protein 1)/caspase-8/FADD complex. Knockdown of RIP1 by small interfering RNA significantly reduces BV6-and TMZ-induced caspase-8 activation and apoptosis, showing that RIP1 is necessary for apoptosis induction. By demonstrating that BV6 primes glioblastoma cells for TMZ in a NF-kB-and RIP1-dependent manner, these findings build the rationale for further (pre)clinical development of Smac mimetics in combination with TMZ.
INTRODUCTION
Glioblastoma is the most common primary malignant brain tumor in adults with a very poor prognosis. 1 The current treatment options include surgical resection, followed by radiation and chemotherapy with the alkylating agent temozolomide (TMZ). 2 As recurrence is quite common, new and more effective therapies are urgently needed.
Evasion of apoptosis, the intrinsic suicide program of the cell, is a characteristic feature of human cancers. 3 Impaired induction of apoptosis can lead to resistance of cancer cells to conventional chemotherapy. 4 Apoptosis is induced by at least two different pathways. 5 The extrinsic (death receptor) pathway is activated by binding of tumor necrosis factor (TNF) super-family proteins to their specific receptors at the cell surface causing activation of the initiator caspase-8. 6 Upon its activation, caspase-8 can directly cleave effector caspase-3 and --7, leading to apoptosis. 6 The intrinsic (mitochondrial) pathway involves mitochondrial outermembrane permeabilization accompanied by the release of cytochrome c and second mitochondria-derived activator of caspases (Smac) into the cytosol. 7 Cytochrome c initiates the formation of a caspase-9-activation platform, that is, the apoptosome, while Smac relieves the inhibition of caspases by neutralizing inhibitor of apoptosis (IAP) proteins. 7 IAP proteins are expressed at high levels in many cancers and have been reported to confer treatment resistance. 8 Therefore, they present promising targets for therapeutic intervention. Synthetically designed Smac mimetics or small-molecule IAP antagonists have been shown to neutralize XIAP, and thus abolish the XIAP-imposed inhibition of caspases. 8 In addition, Smac mimetics can trigger proteasomal degradation of IAP proteins that harbor a RING domain with E3-ligase activity, for example, cellular IAPs (cIAPs). 9, 10 Loss of cIAPs promotes de-ubiquitination of receptor-activating protein 1 (RIP1) and formation of a RIP1/FADD/caspase-8 complex, which drives the activation of caspase-8. 11 In addition, degradation of cIAPs leads to stabilization of NF-kB-inducing kinase (NIK) and activation of the non-canonical NF-kB pathway. 9, 10 Induction of TNFa as a prototype NF-kB target gene has been described to be critical to mediate Smac mimetic-induced apoptosis via an autocrine/ paracrine loop. 9, 10 We previously reported that Smac peptides, which neutralize XIAP, can prime glioblastoma cells for TRAIL-induced apoptosis in vitro and in vivo. 12 In addition, we demonstrated that genetic or pharmacological inactivation of XIAP increases radiation-induced apoptosis in glioblastoma cells. 13, 14 However, it is not yet known whether Smac mimetics could also be used to increase the chemosensitivity of glioblastoma. Searching for novel treatment strategies, we therefore investigated in the present study the potential of the Smac mimetic BV6 to potentiate chemotherapyinduced apoptosis in glioblastoma cells.
RESULTS

BV6 sensitizes glioblastoma cells to TMZ-induced cytotoxicity
To investigate the potential of the small-molecule Smac mimetic BV6 to sensitize glioblastoma cells for chemotherapy-induced apoptosis, we assessed cell viability upon treatment with several anticancer drugs in the presence or absence of BV6 using the glioblastoma cell line A172 as a cellular model of glioblastoma. Treatment with BV6 alone reduced cell viability and induced caspase-dependent apoptosis in a dose-and time-dependent manner (Supplementary Figure 1) . Furthermore, BV6 significantly reduced cell viability following exposure to TMZ or BCNU, while it had little effect on Doxorubicin-or Etoposide-triggered loss of viability ( Figure 1a) . As TMZ is the first-line chemotherapeutic drug for the treatment of glioblastoma, 2 we tested the combination of BV6 and TMZ in additional glioblastoma cell lines to exclude that the synergism is restricted to one particular cell line. Importantly, BV6 cooperated with TMZ to decrease cell viability in several glioblastoma cell lines in a dose-dependent manner (Figure 1b) . Calculation of combination index revealed that the interaction of TMZ and BV6 is highly synergistic (Figure 1c , Table 1 ). Kinetic analysis showed that BV6 reduced cell viability in TMZ-treated cells in a time-dependent manner (Figure 1d ). Together, this set of experiments demonstrates that the Smac mimetic BV6 sensitizes glioblastoma cells towards TMZ. 600  300  100  30  20  0  600  300  100  30  20   0  600  300  100  30  20  0  600  300  100  30  20  0  600  300  100  30 BV6 and TMZ cooperate to induce mitochondrial outer-membrane permeabilization and caspase-dependent apoptosis To explore whether BV6 and TMZ trigger apoptotic cell death, we assessed several characteristic features of apoptosis. BV6 and TMZ cooperated to induce DNA fragmentation and phosphatidylserine exposure as assessed by Annexin-V staining (Figure 2a and Supplementary Figure 2 ). In addition, BV6 significantly increased the loss of mitochondrial membrane potential and the release of cytochrome c from the mitochondria in a time-dependent manner compared with cells treated with TMZ alone (Figures 2b and c) . Also, the combination of BV6 and TMZ accelerated processing of caspase-3 into active cleavage fragments compared with treatment with BV6 alone (Figure 2d ). Inhibition of caspase activity by the broad-range caspase inhibitor zVAD.fmk almost completely prevented the combination treatment-mediated increase in apoptosis and also significantly reduced apoptosis that was triggered by BV6 alone (Figure 2e ). This set of experiments demonstrates that BV6 and TMZ cooperate to cause mitochondrial outer membrane permeabilization, caspase activation and caspasedependent apoptotic cell death.
BV6 causes downregulation of IAP proteins, accumulation of NIK and activation of NF-kB IAP antagonists have been reported to initiate autoubiquitylation and proteasomal degradation of IAP proteins harboring a RING domain with E3 --ligase activity such as cIAP proteins. 9, 10 To gain insights into the underlying mechanisms of the synergism of BV6 and TMZ in glioblastoma cells, we therefore analyzed the effect of single and combination treatment with BV6 and/or TMZ on the expression levels of IAP proteins. Exposure to BV6 or BV6 plus TMZ caused downregulation of cIAP1 and XIAP, whereas treatment with TMZ alone did not alter expression levels of IAP proteins (Figure 3a) . cIAP proteins have recently been identified as E3 ligases that trigger ubiquitylation and proteasomal degradation of NIK. 9, 10 Therefore, we explored NIK stability upon exposure to BV6 and/or TMZ. Treatment with BV6 or the combination of BV6 and TMZ resulted in stabilization of NIK (Figure 3b ). Also, BV6 or BV6 plus TMZ stimulated NF-kB DNA binding (Figure 3c ) and NF-kB transcriptional activity (Figure 3d ). These results demonstrate that BV6 causes the accumulation of NIK and NF-kB activation.
BV6-mediated activation of NF-kB is essential for TMZ-induced apoptosis To elucidate the role of NF-kB in BV6-and TMZ-mediated apoptosis, we used A172 glioblastoma cells that stably express the dominant-negative super-repressor mutant IkBa-S(32,36)A (IkBa-SR) or empty vector control that we generated previously. 15 IkBa-SR is resistant to proteasomal degradation, as it cannot be phosphorylated at the two phosphorylation sites serine 32/36, and thus blocks NF-kB activation. 15 Importantly, inhibition of NF-kB almost completely inhibited the BV6-mediated sensitization to TMZ-induced loss of viability and apoptosis (Figure 4a ). In addition, NF-kB inhibition profoundly suppressed BV6-and TMZinduced cleavage of caspase-8 and -3 into active fragments (Figure 4b) . Also, NF-kB inhibition significantly reduced loss of mitochondrial membrane potential and the release of cytochrome c from the mitochondria (Figures 4c and d) . To investigate the involvement of canonical or non-canonical NF-kB signaling of BV6/TMZ-mediated cell death, we overexpressed a kinase-dead version of IKK2 (IKKb-KD) and knocked down NIK to inhibit canonical-and non-canonical NF-kB signaling, respectively. Overexpression of IKKb-KD significantly reduced BV6/TMZmediated cell death, although NIK knockdown had no effect (Figures 5a and b) .
To explore how NF-kB promotes cell death we monitored expression levels of key pro-and anti-apoptotic signaling proteins. Expression of the short isoform of cFLIP, that is, cFLIP S , was upregulated upon treatment with either BV6, or BV6 and TMZ in a NF-kB-dependent manner (Figure 5c), consistent with its known function as NF-kB target gene. 16 In addition, expression of cIAP2, another NF-kB target gene, 17 TNFa-independent sensitization to TMZ-induced apoptosis by BV6 As induction of apoptosis by monotherapy with IAP antagonists has been attributed to a TNFa-driven, autocrine/paracrine celldeath loop, 9, 10 we hypothesized that activation of NF-kB upon BV6 and TMZ treatment leads to the production of TNFa and subsequently to TNFa-mediated apoptosis. However, to our surprise we found no increased TNFa mRNA expression upon treatment with BV6 or the combination of BV6 and TMZ compared with stimulation with TNFa that was used as a positive control (Figure 6a ). Also, pre-treatment and readdition of the TNFablocking antibody, Enbrel, did not inhibit BV6-or BV6 plus TMZinduced apoptosis compared with the positive control TNFa (Figure 6b ). In addition, Enbrel did not interfere with activation of caspase-8 and -3 upon treatment with BV6 and TMZ ( Figure 6c ). Knockdown of TNFR1 resulted in a minor reduction of BV6/TMZinduced apoptosis (Figure 6d ). Furthermore, the addition of CD95 or TRAIL-blocking antibodies failed to rescue BV6-and TMZinduced apoptosis (Figures 6e and f) . Together, these experiments indicate that death receptor/ligand systems have a minor role in mediating apoptosis upon the combination treatment with BV6 and TMZ.
RIP1 is a critical mediator of BV6-and TMZ-induced apoptosis As IAP antagonists have been shown to promote the formation of a RIP1-dependent caspase-8 activation complex, 11, 18 we asked (Figure 7a ). Of note, the addition of Enbrel did not interfere with the formation of the caspase-8/RIP1/FADD complex (Figure 7a ), indicating that this complex is formed largely independent from an autocrine/ paracrine --TNFa loop. Although TMZ stimulated the interaction of cIAP1 and cIAP2 with caspase-8, the combination treatment resulted in complex formation of caspase-8 with FADD and RIP1 (Supplementary Figure 3A) . As RIP1 can function as a critical regulator of either survival or apoptosis, 19 we next explored whether RIP1 is required for BV6-and TMZ-induced cell death. To this end, we transiently silenced RIP1 by small interfering RNA (Figure 7b) . Importantly, knockdown of RIP1 significantly attenuated the BV6-mediated sensitization toward TMZ-induced apoptosis and also significantly reduced apoptosis upon treatment with BV6 or TMZ alone (Figure 7b,   Supplementary Figure 3B ). To examine whether activation of the caspase cascade occurs in a RIP1-dependent manner, we monitored caspase-8 activation by western blotting. Interestingly, RIP1 knockdown markedly reduced cleavage of caspase-8 into active fragments upon treatment with BV6 and TMZ (Figure 7c ). To explore the functional relevance of caspase-8 in BV6-and TMZinduced cell death, we silenced caspase-8 by RNAi. Of note, knockdown of caspase-8 significantly decreased BV6-and TMZmediated DNA fragmentation (Figure 7d ). Together, this set of experiments demonstrates that RIP1 has a key role in mediating BV6-and TMZ-induced caspase-8 activation and apoptosis. DISCUSSION Glioblastoma, the most frequent primary malignant brain tumor in adulthood, bears a very poor prognosis, calling for novel treatment strategies. 1 Here, we report for the first time that the Smac mimetic BV6 represents a promising new approach to prime glioblastoma cells to TMZ-induced apoptosis, the first-line chemotherapeutic agent in the treatment of glioblastoma. This Smac mimetic potentiates TMZ-induced apoptosis L Wagner et al conclusion is based on the following independent lines of evidence: First, the Smac mimetic BV6 cooperates with TMZ to induce apoptosis in glioblastoma cells in a synergistic manner as calculated by combination index. Several glioblastoma cell lines are presented to confirm the generality of this finding. Second, we identify NF-kB and RIP1 as critical mediators of the BV6-mediated sensitization to TMZ-triggered apoptosis. Third, we show for the first time that BV6 and TMZ act together to induce the formation of a RIP1-dependent caspase-8 activation complex. Importantly, this RIP1/caspase-8/FADD complex formation and induction of apoptosis upon treatment with BV6 and TMZ occurs with little involvement of autocrine/paracrine TNFa-mediated stimulation of TNFR1.
The novelty of the present study resides in the demonstration that BV6 confers increased sensitivity toward TMZ in a RIP1-and NF-kB-dependent manner. BV6 and TMZ cooperate to stimulate the formation of a RIP1/FADD/caspase-8 signaling complex that drives caspase-8 activation. We identify RIP1 as an essential mediator of BV6-and TMZ-triggered apoptosis, as knockdown of RIP1 inhibits activation of caspase-8 and subsequent apoptosis upon treatment with BV6 or BV6 and TMZ. Interestingly, BV6 and TMZ trigger the assembly of the RIP1/FADD/caspase-8 complex and subsequent activation of caspases with little involvement of an autocrine/paracrine TNFa loop, as the TNFa-blocking antibody Enbrel or TNFR1 knockdown have no or minor effect on its formation. In addition, CD95 or TRAIL-blocking antibodies fail to rescue BV6-and TMZ-induced apoptosis. RIP1 mediates apoptotic cell death rather than necroptosis in this model of cell death, as supported by the detection of several characteristic features of apoptosis and little RIP3 protein expression in A172 cells (data not shown). Furthermore, NF-kB is required for the BV6-mediated potentiation of TMZ-induced apoptosis, as specific inhibition of NF-kB by the dominant-negative IkBa-SR significantly reduces apoptosis upon combination treatment. This pro-apoptotic function of NF-kB is in line with our previous findings showing that NF-kB is required for the DNA-damage response and apoptosis upon treatment with anticancer drugs in glioblastoma cells. 15 TNFa, a prototypic NF-kB target gene, turned out to be largely dispensable for apoptosis induction, as pretreatment with Enbrel or TNFR1 knockdown failed to rescue apoptosis upon combination treatment. By comparison, previous studies have shown that apoptosis upon treatment with Smac mimetics as single agents relies on their ability to stimulate TNFa production. 9, 10 In addition, an autocrine TNFa loop has been implicated in the chemosensitization of colon, pancreatic and breast carcinoma cells by the Smac mimetic. 20 Together, these results indicate that both TNFa-dependent and -independent pathways are involved in the Smac mimetic-mediated modulation of apoptosis in a context-dependent manner. Thus, autocrine TNFa production may not serve as a biomarker for the responsiveness toward Smac mimetics in all circumstances. BV6 and TMZ may cooperate in this model of apoptosis by inducing the formation of the RIP1/FADD/caspase-8 complex (that is, BV6) and by triggering the DNA damage response involving increased p53 and Bax expression (that is, TMZ).
Of note, BV6 was found to enhance in particular the cytotoxicity of alkylating agents such as TMZ and BCNU, which are both used in the treatment of glioblastoma. 2 By comparison, no cooperative interaction of BV6 was detected together with topoisomerase II inhibitors such as Doxorubicin and Etoposide. It will be interesting to explore in further studies whether or not BV6 interferes with a specific type of DNA damage or repair pathway.
Our findings have important implications for the development of novel approaches for the treatment of glioblastoma. Accordingly, our results suggest that the incorporation of small-molecule Smac mimetics into TMZ-based protocols presents a promising strategy to enhance the sensitivity of glioblastoma toward TMZ, the first-line anticancer drug that is used for glioblastoma therapy. 2 As small-molecule Smac mimetics are currently under evaluation as single agents in first clinical trials, 21 it appears feasible that such an approach can in principle be translated into a clinical application. In conclusion, by showing that the Smac mimetic BV6 primes glioblastoma cells to TMZ-induced apoptosis, our findings build the rationale for further (pre)clinical development of Smac mimetics in combination with TMZ as a novel treatment approach in glioblastoma.
MATERIALS AND METHODS
Cell culture and chemicals
Human glioblastoma cell lines U87MG, A172, U118 and D54 were obtained from ATCC (Manassas, VA, USA) and grown in DMEM medium (Invitrogen, Karlsruhe, Germany) supplemented with 1% penicillin/streptomycin, 1 mmol/l L-glutamine (both from Invitrogen), 10% fetal calf serum and 25 mmol/l HEPES (both from Biochrom AG, Berlin, Germany). For experiments, cells were seeded at 0.1 Â 10 5 cells/cm 2 . Smac mimetic BV6 9 was produced at Genentech (South San Francisco, CA, USA), TMZ was kindly provided by the National Cancer Institute (Bethesda, MA, USA), BCNU, Doxorubicin and Etoposide were purchased from Sigma (SigmaAldrich, Taufkirchen, Germany), recombinant human TNFa from Biochrom, the broad-spectrum caspase inhibitor benzyloxycarbonyl-Val-Ala-Aspfluoromethyl ketone (zVAD.fmk) from Bachem (Bubendorf, Switzerland), anti-CD95 (purified NA/LE mouse anti-human CD178) from BD Pharmingen and anti-TRAIL (mAb 2E5) from Enzo Life Sciences. Enbrel was kindly provided by Pfizer (Berlin, Germany).
Determination of apoptosis and cell viability
Apoptosis was assessed by fluorescence-activated cell-sorting (FACScan, Becton Dickinson, Heidelberg, Germany) analysis of the DNA fragmentation of propidium-iodide-stained nuclei as described previously. 22 Briefly, cells were fixed and lysed for 3 h in a solution of 0.1% tri-sodium citrate dehydrate and 0.1% Triton X-100 containing 50 mg/ml propidium iodide (Sigma, Deisenhofen, Germany) and analyzed by FACScan. In Jurkat leukemia cells, apoptosis was determined by forward side-scatter analysis as described previously. 23 Cell viability was determined by incubation with the colorimetric substrate methylthiazol tetrazolium using the 3-[4,5]dimethylthiazol-2,5-diphenyl tetrazolium bromide assay according to the manufacturer's instruction (Roche Diagnostics, Mannheim, Germany). Absorbance was measured using the plate reader (ELX 800, Bio-tek Instruments GmbH, Bad-Friedrichshall, Germany).
Western blot analysis
Western blot analysis was performed as described previously 22 using the following antibodies: mouse anti-caspase-8 (1:1000) and mouse anti-cFLIP (1:5000) from Alexis Biochemicals (Epalinges, Switzerland), rabbit anticaspase-3 (1:1000) and rabbit anti-Bid (1:1000) from Cell Signaling (Beverly, MA, USA), mouse anti-XIAP, mouse anti-FADD, mouse anti-RIP1 mouse anti-Bcl-2, mouse anti-p53 and rabbit-anti Bcl-X L (1:1000) from BD Biosciences (Heidelberg, Germany), goat anti-cIAP1 and rabbit anti-survivin (1:1000) from R&D Systems, Inc. (Wiesbaden, Germany), rabbit anti-cIAP2 (1:1000; Epitomics, Burlingame, CA, USA), NIK(1:1000; Cell Signaling), rabbit anti-BaxNT (1:5000) from Upstate Biotechnology (Lake Placid, NY, USA), mouse anti-b-actin (1:5000; Sigma), mouse anti-TNFR1 (1:1000) or goatanti-mouse IgG, goat-anti-rabbit IgG or donkey-anti-goat IgG conjugated to horseradish peroxidase (1:5000; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Enhanced chemiluminescence was used for detection (Amersham Bioscience, Freiburg, Germany). All western blots shown are representative of at least three independent experiments.
Determination of mitochondrial membrane potential and cytochrome c release To determine mitochondrial transmembrane potential, cells were incubated with CMXRos (1 mmol/l; Molecular Probes, Karlsruhe, Germany) for 30 min at 37 1C and immediately analyzed by flow cytometry. Cytochrome c release was determined in permeabilized cells using mouse anti-cytochrome c monoclonal antibody (1:40; BD Bioscience, Freiburg, Germany) as previously described. 24 Nuclear protein extraction and electrophoretic mobility shift assay(EMSA) Nuclear protein extraction and EMSA were performed as described previously. 15 In brief, after appropriate incubation, cells were washed, scraped and collected by centrifugation at 1000 Â g for 5 min at 4 1C. Cells were resuspended in low salt buffer (10 mM HEPES-OH pH 7.9; 1.5 mM MgCl 2 ; 10 mM KCl) and allowed to swell for 15 min on ice. After addition of 10% Igepal CA-g30 (Sigma-Aldrich) solution, samples were mixed vigorously, nuclei were collected by centrifugation, resuspended in highsalt buffer (20 mM HEPES-OH pH 7.9; 420 mM NaCl; 1.5 mM MgCl 2 ; 0.2 mM EDTA; 25% glycerol), incubated on ice and vortexed for 20 min. Nuclear supernatants were obtained by centrifugation at 12 500 g at 4 1C for 20 min. Protein concentration was determined by the BCA Protein Assay Kit (Pierce, Rockford, IL, USA) according to the manufacturer's instruction. For EMSA the following sequence was used as specific labeled oligomer for NF-kB: 5 0 -AGTTGAGGGGACTTTCCCAGGC-3 0 (sense). Single-stranded oligonucleotides were labeled with gamma-[ 32 P]-ATP by T4-polynucleotide kinase (MBI Fermentas GmbH, St Leon-Rot, Germany), annealed to the complementary oligomer strand and purified on sephadex columns (Micro Bio-Spin P30, Biorad Laboratories, Munich, Germany). Binding reactions, containing 5 mg nuclear extract, 1 mg Poly(dI:dC) (Sigma), 2 pmol labeled oligonucleotide and 5 Â binding buffer were incubated for 30 min on ice. Binding complexes were resolved by electrophoresis in non-denaturating 6% polyacrylamide gels using 0.3 Â TBE as running buffer and assessed by autoradiography. Representative EMSAs are shown. 
